Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Potentiating the tumor-restraining properties of the stroma in pancreatic cancer with small molecules
Umeå University, Faculty of Medicine, Department of Radiation Sciences.
Umeå University, Faculty of Medicine, Umeå Centre for Molecular Medicine (UCMM). Umeå University, Faculty of Science and Technology, Department of Chemistry.
Show others and affiliations
(English)Manuscript (preprint) (Other academic)
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-215329OAI: oai:DiVA.org:umu-215329DiVA, id: diva2:1805682
Available from: 2023-10-18 Created: 2023-10-18 Last updated: 2023-10-18
In thesis
1. The identification and functional evaluation of novel cancer-associated fibroblast subtypes and matrisome proteins in pancreatic cancer
Open this publication in new window or tab >>The identification and functional evaluation of novel cancer-associated fibroblast subtypes and matrisome proteins in pancreatic cancer
2023 (English)Doctoral thesis, comprehensive summary (Other academic)
Alternative title[sv]
Identifiering och funktionell utvärdering av nya cancer-associerade fibroblast-subtyper och matrisomeproteiner i pankreascancer
Abstract [en]

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an extensive desmoplastic stroma. The stroma is the site of intricate communication between malignant cells and their surrounding environment. This tissue microenvironment (TME) is populated by a heterogenous mixture of cell types and extracellular matrix proteins. Distinct stromal elements confer tumour-restraining or tumour-promoting influences on tumorigenesis. Characterizing stromal composition therefore represents an opportunity to identify candidates for therapeutic intervention to facilitate improved clinical outcomes. In this thesis we identify galectin-4 as an extracellular matrix protein which is upregulated in PDAC. We find that galectin-4 exerts a pro-tumorigenic influence in PDAC through promoting immune suppression, highlighting its potential as a novel therapeutic target. We subsequently provide a comprehensive characterization of mesenchymal cell diversity in PDAC including cancer-associated fibroblasts (CAFs) which represent one of the dominant stromal cellular components. We identify inflammatory CAF (iCAF) and myofibroblastic CAF (myCAF) subtypes in addition to defining a novel interferon-response CAF (ifCAF) subtype. In addition, we demonstrate that pancreatic stellate cells (PSCs) are capable of forming iCAFs, myCAFs and ifCAFs in response to tumour-derived signals using an organoid-based co-culture model and define biological pathways regulating CAF subtype formation. We then perform a high-throughput drug-screen using this co-culture model to identify compounds which can suppress tumour growth indirectly through modifying CAFs. One such compound is GNF-5 which we show can suppress cancer cell proliferation indirectly through manipulating CAF phenotype. Taken together, this thesis augments our understanding of the composition of the PDAC stroma and identifies potential therapeutic targets as well as developing an approach to discover drugs which yield a therapeutic benefit through targeting the PDAC stroma.   

Place, publisher, year, edition, pages
Umeå: Umeå University, 2023. p. 122
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 2259
Keywords
Cancer-associated fibroblast (CAF), Single-cell RNA sequencing (scRNAseq), Pancreatic ductal adenocarcinoma (PDAC), Tumor microenvironment (TME), Extracellular matrix (ECM), Organoid-based co-culture model, Drug-screen
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
urn:nbn:se:umu:diva-215330 (URN)9789180701747 (ISBN)9789180701754 (ISBN)
Public defence
2023-11-17, Betula, 6M, Norrlands universitetssjukhus, Umeå, 13:00 (English)
Opponent
Supervisors
Available from: 2023-10-26 Created: 2023-10-18 Last updated: 2023-10-19Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records

Mason, JamesCumming, JoshuaEriksson, Anna U.Dongre, MiteshPatthey, CedricChorell, ErikÖhlund, Daniel

Search in DiVA

By author/editor
Mason, JamesCumming, JoshuaEriksson, Anna U.Dongre, MiteshPatthey, CedricChorell, ErikÖhlund, Daniel
By organisation
Department of Radiation SciencesUmeå Centre for Molecular Medicine (UCMM)Department of ChemistryDepartment of Molecular Biology (Faculty of Medicine)Molecular Infection Medicine Sweden (MIMS)Wallenberg Centre for Molecular Medicine at Umeå University (WCMM)Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 165 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf